Kymera Therapeutics, Inc. SEC Filings

Form 4 filed for Kymera Therapeutics (KYMR) on 30 June 2025 details a sizable insider purchase by the Baker Brothers funds. Two affiliated limited partnerships—667, L.P. and Baker Brothers Life Sciences, L.P.—acquired both common shares and prefunded warrants in an underwritten offering that closed the same day.

• Common stock: 55,191 shares bought by 667, L.P. and 600,309 shares bought by Life Sciences at $44.00 per share.
• Prefunded warrants: Matching blocks of 55,191 and 600,309 warrants purchased at $43.9999 per warrant, exercisable at $0.0001 on a 1-for-1 basis.
• Post-transaction beneficial ownership rises to ~6.65 million common shares and ~11.2 million prefunded warrants across the two funds.
• The warrants carry no expiration but include a 4.99 % beneficial-ownership cap (adjustable up to 19.99 % with 61-day notice) to avoid triggering reporting thresholds.
• Felix J. Baker sits on Kymera’s board; the remaining reporting persons are deemed “directors by deputization.”

The sizeable investment, executed at the public offering price, signals confidence from a well-known biotech investor group, but also adds new equity and derivative securities that modestly dilute existing shareholders.

Kymera Therapeutics (NASDAQ: KYMR) has entered into a definitive underwriting agreement for a sizeable follow-on equity offering. The company will issue 5,044,500 new common shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 per warrant, equivalent to the share price less the $0.0001 exercise price. Underwriters have a 30-day option to purchase up to 855,000 additional shares.

Gross proceeds could reach $272.7 million if the option is fully exercised; net proceeds are estimated at $237.3 million (or $272.7 million including the option) after fees and expenses. Management plans to deploy the capital to advance its protein-degrader pipeline, expand clinical programs, and for general corporate purposes. With existing cash plus the offering proceeds, Kymera projects a cash runway into mid-2028.

The pre-funded warrants are immediately exercisable, subject to ownership limits (initially 4.99 % or 9.99 %, adjustable up to 19.99 %). They will not be listed on any exchange. The company also executed a Registration Rights Agreement covering up to 27,963,945 shares held by affiliated funds (Baker Brothers, Atlas Venture, and BVF Partners), allowing resale registration requests beginning 28 Feb 2026.

Press releases announcing the launch and pricing were issued on 25-26 Jun 2025. The transaction strengthens liquidity but introduces dilution, as the new shares and warrant exercises could expand the share count by roughly 6.6 million (plus any over-allotment), representing a high-single-digit percentage of the current float.

Kymera Therapeutics (NASDAQ:KYMR) filed an 8-K disclosing the June 25 2025 annual shareholder meeting results. Shareholders re-elected Jeffrey Albers and Felix Baker as Class II directors, approved the non-binding advisory vote on executive compensation, and ratified Ernst & Young as the independent auditor for fiscal 2025. No additional matters were submitted.

Kymera Therapeutics announced a public offering of 5,044,500 shares of common stock at $44.00 per share and 655,500 pre-funded warrants at $43.9999 per warrant. The total offering is expected to raise approximately $250.8 million before underwriting discounts and commissions.

Key offering details:

• Net proceeds before expenses: $237.9 million
• Underwriters granted 30-day option to purchase additional 855,000 shares
• Pre-funded warrants have $0.0001 exercise price with no expiration date
• Joint book-running managers include Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen, and Leerink Partners

The offering is expected to close on June 30, 2025. The pre-funded warrants will not be listed on Nasdaq. Proceeds will support research and development programs, including TYK2, IRF5, STAT6, and IRAK4 programs, as well as potential IND submissions to the FDA.

Kymera Therapeutics (KYMR) reported insider trading activity on June 28, 2025, involving stock options granted to Baker Bros. Advisors LP and affiliated entities. Felix J. Baker, a director of Kymera, received 16,000 non-qualified stock options with the following terms:

• Exercise price: $46.47 per share
• Grant date: June 25, 2025
• Expiration date: June 24, 2035
• Vesting: Earlier of first anniversary or next annual stockholder meeting

The filing details complex beneficial ownership arrangements where Baker Bros. Advisors LP serves as investment adviser to two funds: Baker Brothers Life Sciences LP and 667 LP. Per adviser policies, Felix Baker has no direct pecuniary interest in the options, with all economic benefits flowing to the funds. Julian Baker and Felix Baker may have indirect interests through their ownership in the funds' general partners. Baker Bros. Advisors LP maintains complete voting and investment control over the securities.

Form 4 Filing Details: Jeffrey W. Albers, Director of Kymera Therapeutics (KYMR), received a stock option grant on June 25, 2025. The derivative securities transaction involved:

• Grant of 16,000 stock options to purchase common stock
• Exercise price set at $46.47 per share
• Options expire on June 24, 2035
• Vesting schedule: Full vesting upon earlier of June 25, 2026 or next annual stockholder meeting

The transaction was reported via Form 4 filing on June 28, 2025, with Bruce Jacobs signing as Attorney-in-Fact. This equity compensation grant appears to be part of the company's director compensation program, with Albers maintaining direct ownership of the derivative securities.

Kymera Therapeutics, Inc. (KYMR) filed a Form 4 on 26 June 2025 disclosing a single equity transaction for director Gorjan Hrustanovic. The filing reports the grant of a stock option covering 16,000 common shares with an exercise price of $46.47 per share.

The option was issued on 25 June 2025 and carries a ten-year term, expiring 24 June 2035. Vesting occurs in full on the earlier of (i) 25 June 2026 or (ii) the date of Kymera’s next annual shareholders’ meeting. No common shares were bought or sold in the open market; the transaction is classified as an "A" (grant) under SEC codes.

The reporting person is a member of BVF Partners L.P. and has agreed to transfer any economic benefit from the option to BVF; consequently, beneficial ownership is disclaimed beyond any pecuniary interest. Following the grant, Hrustanovic holds 16,000 derivative securities directly and reports no change in underlying common-stock ownership.

For investors, this appears to be a routine director compensation grant rather than a signal of changing sentiment or material corporate development. No immediate impact on Kymera’s capitalization, earnings outlook, or governance profile is indicated.

Form 4 Filing Details: Kymera Therapeutics (KYMR) director Pamela Esposito received a stock option grant on June 25, 2025. The derivative security consists of options to purchase 16,000 shares of common stock at an exercise price of $46.47 per share.

The stock options have the following key terms:

• Expiration date: June 24, 2035
• Vesting schedule: Full vesting upon the earlier of June 25, 2026, or the next annual stockholders' meeting
• Ownership form: Direct

This grant appears to be part of the company's director compensation program. The filing was signed by Bruce Jacobs as Attorney-in-Fact on June 26, 2025.

Form 4 Filing Details: Director John Maraganore of Kymera Therapeutics (KYMR) received a stock option grant on June 25, 2025, representing a significant insider transaction.

Key Transaction Details:

• Acquired 16,000 stock options with exercise price of $46.47 per share
• Options expire on June 24, 2035
• Vesting occurs at earlier of June 25, 2026 or next annual stockholder meeting
• Transaction reported as direct ownership

This grant appears to be part of the company's director compensation program. The options provide Maraganore with the right to purchase KYMR shares at the specified strike price, aligning his interests with shareholders through potential stock price appreciation over the next decade.